Company
Cspc Ouyi
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
0 still marketed
Novel approvals
0
Approvals since 2021
0
Originals and new uses
Phase 3 trials
10
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Conjupri approved Dec 19, 2019
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive DisorderPivotal-lookingRecruiting
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT06958692 · 388 participants (planned) · Start Apr 11, 2025 · Primary completion Sep 30, 2026
Drug: Dextromethorphan and Bupropion Sustained-Release Tablets; Placebo · For: Major Depressive Disorder (MDD)
Sites: Beijing, China
Marketed drugs (0)
Newest FDA action first.
None still marketed under these names.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.